G2GBIO Inc. (KOSDAQ:456160)

South Korea flag South Korea · Delayed Price · Currency is KRW
103,100
-2,400 (-2.27%)
At close: Feb 26, 2026
257.57%
Market Cap 1.78T
Revenue n/a
Net Income n/a
Shares Out 16.42M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 626,124
Average Volume 868,031
Open 104,700
Previous Close 105,500
Day's Range 99,500 - 106,600
52-Week Range 27,567 - 111,900
Beta n/a
RSI 69.31
Earnings Date n/a

About G2GBIO

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal ca... [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456160
Full Company Profile

News

There is no news available yet.